Novavax, Inc.
Novavax, Inc. develops vaccines to combat serious infectious diseases using a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant. The company focuses on urgent health challenges like COVID-19, influenza, and malaria. It commercializes a COVID-19 vaccine for adult and adolescent populations as well as booster indications. Novavax also develops an R21/Matrix-M adjuvant malaria vaccine.
Overview
Strengths
- Our discounted cash flow model points to 183% upside (target price 27.66 USD), and even our pessimistic growth scenario implies 143%: a margin of safety.
- Valued below its Biotechnology peers: P/E 3.6x vs. a median of 20.4x and EV/EBITDA 2.6x vs. a median of 15.6x.
- Consistent growth: revenue has compounded at 118.8% a year over 5 years, rising in 4 of them.
- EBITDA margin of 55.1% beats 91% of its 128 Biotechnology peers (median 0.0%).
- Improving fundamentals over the last year: return on assets up 49.4 points and gross margin up 23.2 points.
- Cheaper than its own history: P/E 3.6x vs. a historical average of 83.8x and EV/EBITDA 2.6x vs. a historical average of 83.7x.
Weaknesses
- Eroding returns: ROIC has fallen to 0.0% from a multi-year average of 53.7%, a possible sign of a weakening moat.
- Shareholder dilution: the share count has grown by 23.6% a year over the last three years.
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Unstable profitability: operating margin ranged from -1,861% to 49% over the last 6 years, with operating losses in 5 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 58.2% of total assets.
Key Financial Data